Clinical Trial

EVALUATION OF SALIVA AS LIQUID BIOPSY FOR EARLY DETECTION OF ORAL CANCER IN PATIENTS WITH ORAL-SUBMUCOUS FIBROSIS (OSMF)

Study acronym: Sal
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 14, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Oral cancer is the top cancer in Pakistan, accounting for 27%, and it has a high mortality rate due to late-stage diagnosis. It primarily affects the lips, tongue, cheeks, and floor of the mouth. Major risk factor for oral cancer development is pan supari chhaliya chewing. Patients often develop a pre-malignant condition, oral submucous fibrosis, resulting in limited mouth opening. Thus, patients are diagnosed at an advanced level and poor survival. Therefore, saliva appears a potential mode of evaluation for early detection. This project aims to evaluate salivary cells, genes and biochemistry of the saliva among health volunteers and compare it with that of the patients with oral submucous fibrosis and oral cancer.
Trial Details
NCT Number NCT07122128
Lead Sponsor Liaquat University of Medical & Health Sciences
Collaborators: Sindh Higher Education Commission
Conditions The Study Focuses on the Saliva as Potential Source of Early Detection of Oral Cancer
Enrollment 1,000 participants
Start Date 2021-06-01
Primary Completion 2025-12-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-14